Thioredoxin increases redox-cycling of anticancer agents thereby sensitizes cancer cells to apoptosis

• US 20050208037A1
• Filed: 10/21/2004
• Published: 09/22/2005
• Est. Priority Date: 10/21/2003
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Das, Kumuda C., Dashnamoorthy, Ravi
• Application Number:
  US10/970,370
• Publication Number:
  US 20050208037A1
• Time in Patent Office: Days
• US Class Current: 424/94.400
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: C12Y 108/01008 Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Abstract

The present invention provides for treatment of cancer by enhancing the effectiveness of anticancer agents. The present invention therefore provides methods of increasing the apoptotic potential of anticancer drugs by increasing the expression of the cellular redox protein thioredoxin or thioredoxin-like molecules and thereby sensitizing the cancer to the anticancer agent. The present invention also provides methods of ameliorating negative side-effects of an anticancer therapy comprising a thioredoxin or a thioredoxin-like molecule and an anticancer therapy.

Claims

1. A method of treating a subject comprising administering to the subject a therapeutically effective amount of a thioredoxin or a thioredoxin-like molecule and providing to the subject an anticancer therapy.

2. The method of claim 1, wherein the thioredoxin or thioredoxin-like molecule enhances the redox-cycling of the anticancer therapy thereby promoting cell killing.

3. The method of claim 1, wherein the subject has cancer.

4. The method of claim 3, wherein the cancer is a premalignant cancer.

5. The method of claim 3, wherein the cancer is a malignant cancer.

6. The method of claim 3, wherein the cancer is a metastatic cancer.

7. The method of claim 3, wherein the cancer is a breast cancer, lung cancer, head and neck cancer, bladder cancer, bone cancer, bone marrow cancer, brain cancer, colon cancer, esophageal cancer, gastrointestinal cancer, gum cancer, kidney cancer, liver cancer, nasopharynx cancer, ovarian cancer, prostate cancer, skin cancer, stomach cancer, testis cancer, tongue cancer;

or uterine cancer.

8. The method of claim 7, wherein the cancer is breast cancer.

9. The method of claim 1, wherein the anticancer therapy comprises administration of a chemotherapeutic agent.

10. The method of claim 9, wherein the thioredoxin or thioredoxin-like molecule enhances the redox-cycling of the chemotherapeutic agent.

11. The method of claim 9, wherein the chemotherapeutic agent is an anthracycline.

12. The method of claim 11, wherein the anthracycline is doxorubicin.

13. The method of claim 11, wherein the anthracycline is daunomycin.

14. The method of claim 1, wherein the anticancer therapy comprises administration of a radiotherapeutic agent.

15. The method of claim 14, wherein the anticancer therapy comprises radiation.

16. The method of claim 1, wherein thioredoxin or thioredoxin-like molecule is administered before the anticancer therapy.

17. The method of claim 1, wherein the thioredoxin or thioredoxin-like molecule is administered at the same time as the anticancer therapy.

18. The method of claim 1, wherein the thioredoxin or thioredoxin-like molecule is administered once or more than once.

19. The method of claim 1, wherein the thioredoxin or thioredoxin-like molecule is administered intravenously, intradermally, intramuscularly, intraarterially, intralesionally, percutaneously, subcutaneously, or by an aerosol.

20. The method of claim 1, wherein the thioredoxin or thioredoxin-like molecule is administered directly to the tumor.

21. The method of claim 1, wherein the anticancer therapy is provided once or more than once.

22. The method of claim 1, wherein the anticancer therapy comprises administration of an anticancer agent and the anticancer agent is administered intravenously, intradermally, intramuscularly, intraarterially, intralesionally, percutaneously, subcutaneously, or by an aerosol.

23. The method of claim 1, further comprising delivering to a subject an expression construct comprising a nucleic acid encoding a thioredoxin or a thioredoxin-like molecule.

24. The method of claim 23, wherein the expression construct is a viral vector.

25. The method of claim 24, wherein the viral vector is an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a lentiviral vector, a herpes viral vector, polyoma viral vector or hepatitis B viral vector.

26. The method of claim 24, wherein the viral vector is an adenoviral vector.

27. The method of claim 1, further comprising a gene therapy.

28. The method of claim 27, further comprising an adenoviral gene therapy.

29. The method of claim 1, wherein the subject is a mammal.

30. The method of claim 29, wherein the mammal is a human.

31. A method of sensitizing a cancer cell to an anticancer agent comprising providing an effective amount of a thioredoxin or a thioredoxin-like molecule and an anticancer therapy to the cancer cell.

32. The method of claim 31, wherein the thioredoxin or thioredoxin-like molecule enhances the redox-cycling of the anticancer agent.

33. The method of claim 31, further comprising inducing apoptosis in the cancer cell.

34. The method of claim 31, wherein the cancer cell is a premalignant cancer cell.

35. The method of claim 31, wherein the cancer cell is a malignant cancer cell.

36. The method of claim 31, wherein the cancer cell is a metastatic cancer cell.

37. The method of claim 31, wherein the cancer cell is a breast cancer cell, lung cancer cell, head and neck cancer cell, bladder cancer cell, bone cancer cell, bone marrow cancer cell, brain cancer cell, colon cancer cell, esophageal cancer cell, gastrointestinal cancer cell, gum cancer cell, kidney cancer cell, liver cancer cell, nasopharynx cancer cell, ovarian cancer cell, prostate cancer cell, skin cancer cell, stomach cancer cell, testis cancer cell, tongue cancer cell, or uterine cancer cell.

38. The method of claim 37, wherein the cancer cell is breast cancer cell.

39. The method of claim 31, wherein the anticancer therapy comprises administration of a chemotherapeutic agent.

40. The method of claim 39, wherein the chemotherapeutic agent is an anthracycline.

41. The method of claim 40, wherein the anthracycline is doxorubicin.

42. The method of claim 40, wherein the anthracycline is daunomycin.

43. The method of claim 31, wherein the anticancer therapy comprises administration of a radiotherapeutic agent.

44. The method of claim 43, wherein the anticancer therapy comprises radiation.

45. The method of claim 31, wherein the cell is located in a tissue culture.

46. The method of claim 31, wherein the cell is located in a subject.

47. A method of ameliorating negative side-effects of an anticancer therapy in a subject comprising administering to the subject a therapeutically effective amount of a thioredoxin or a thioredoxin-like molecule and an anticancer therapy.

48. A pharmaceutical combination comprising a thioredoxin or a thioredoxin-like molecule and an anticancer agent.

49. The pharmaceutical combination of claim 48, wherein the anticancer agent is a chemotherapeutic agent.

50. The pharmaceutical combination of claim 49, wherein the chemotherapeutic agent is an anthracycline.

51. The pharmaceutical combination of claim 50, wherein the anthracycline is doxorubicin.

52. The pharmaceutical combination of claim 50, wherein the anthracycline is daunomycin.

53. The pharmaceutical combination of claim 48, wherein the thioredoxin or a thioredoxin-like molecule and the anticancer agent are comprised together in a pharmaceutically acceptable excipient.

54. The pharmaceutical combination of claim 48, wherein the thioredoxin or a thioredoxin-like molecule and the anticancer agent are each separately comprised in a pharmaceutically acceptable excipient.